Gordian Surgical Ltd. is a commercial-stage medical device company based in Misgav, Israel. The company develops the TroClose1200, a closure system that places sutures to close the internal tissue layer at the start of a procedure and anchors them throughout surgery. At the end of the procedure the internal incisions are closed upon extraction of the system. Gordian Surgical holds FDA clearance and a CE mark for the TroClose1200. Led by CEO Zvi Pe’er, the company is a portfolio company of The Trendlines Group Ltd. The recently raised funds will be used to ramp up commercialization. Gordian Surgical developed the TroClose1200, an innovative trocar with an integrated closure system that allows surgeons to insert and anchor sutures at the start of a procedure and close incisions quickly upon device removal. The device provides two-in-one functionality, acting both as a trocar and as a closure system for abdominal wall incisions. Gordian received US FDA clearance for the TroClose1200 following CE Mark certification in September. The company says the device has major market potential and generated significant interest at MEDICA 2016. The funds raised will be used to start marketing and distribution in the US and Europe. Gordian was founded in late 2012 by CEO Zvi Pe'er and is a Trendlines Medical portfolio company based at the Misgav Business Center in the Western Galilee. Gordian Surgical builds a two-in-one trocar that inserts sutures at the start of laparoscopic procedures and allows efficient closure when the trocar is removed. The device is designed to reduce the time and difficulty of closing access ports in minimally invasive surgery. An estimated 4.4 million laparoscopic procedures are performed annually in the U.S., highlighting the addressable clinical need the product targets. Gordian is a portfolio company of Trendlines Medical and recently completed a $1 million raise that exceeded its target by 30%. The company plans to use the funds to finalize product design, obtain regulatory clearance (FDA and CE mark), and perform clinical validations. Surgeons’ investments and endorsements from other clinicians were cited as support for the product’s clinical relevance.

Total raised

$6M

Funding rounds

3

Latest round

Equity

Latest activity

Oct 2019